drugset
Drugs / Hydroxychloroquine
last change 10 days ago re-read 9 days ago

Hydroxychloroquine

also known as HCQ · hydroxychloroquine sulfate · Plaquenil · Quensyl · Hydrochloroquine · Hydroxychloroquine Sulphate · CASnr 118-42-3 (hydroxychloroquine); 737-36-4 (hydroxychloroquine sulfate) · Dolquine · +20 more

Small molecule targets ACE2, TLR2, TLR4, TLR7, TLR9 via inhibition

Developed for
COVID-19 · malignant pancreatic neoplasm · colorectal cancer · rheumatoid arthritis · breast cancer · prostate cancer · non-small cell lung carcinoma · pancreatic adenocarcinoma
+149 more · melanoma · pregnancy loss, recurrent, 4 · antiphospholipid syndrome · autoimmune thrombocytopenia · IgA glomerulonephritis · Orthocoronavirinae infectious disease · plasma cell myeloma · severe acute respiratory syndrome · acute respiratory distress syndrome · cancer · cutaneous melanoma · habitual spontaneous abortion · hepatocellular carcinoma · HIV infectious disease · neoplasm · pulmonary sarcoidosis · systemic lupus erythematosus · type 2 diabetes mellitus · acute myeloid leukemia · adenocarcinoma · autoimmune thyroid disease · cancer of unknown primary site · chronic respiratory distress with surfactant metabolism deficiency · coronary artery disorder · digestive system cancer · female breast carcinoma · Hashimoto thyroiditis · interstitial lung disease · lung cancer · lung disorder · obesity disorder · preeclampsia · pregnancy disorder · renal cell carcinoma · respiratory failure · Sjogren syndrome · viral pneumonia · adult acute respiratory distress syndrome · alopecia areata · ankylosing spondylitis · arteriosclerosis disorder · arthritic joint disease · atherosclerosis · atopic eczema · atrial fibrillation · B-cell chronic lymphocytic leukemia · Behcet disease · biliary tract cancer · bone neoplasm · breast carcinoma · central nervous system neoplasm · chemotherapy-induced neuropathy · cholangiocarcinoma · chronic graft versus host disease · chronic hepatitis C virus infection · cirrhosis of liver · clear cell renal carcinoma · clear cell sarcoma · colon carcinoma · colorectal carcinoma · congenital heart block · Crohn disease · cystic fibrosis · digestive system neoplasm · disease of orbital part of eye adnexa · eosinophilic granulomatosis with polyangiitis · estrogen-receptor positive breast cancer · gastroesophageal junction adenocarcinoma · gestational diabetes · glioblastoma · hematopoietic and lymphoid cell neoplasm · hepatitis C virus infection · hidradenitis suppurativa · high grade malignant neoplasm · hilar cholangiocarcinoma · hormone receptor-positive breast cancer · infectious disorder of the nervous system · infertility disorder · interstitial lung disease specific to childhood · leukemia · lichen planus, oral · low grade glioma · lung adenocarcinoma · lung carcinoma · lymphangioleiomyomatosis · mastocytosis · metastatic carcinoma · metastatic melanoma · metastatic neoplasm · microscopic polyangiitis · mucositis · myelodysplastic syndrome · myocardial infarction · NAFLD1 · nasopharyngeal carcinoma · obstructive sleep apnea syndrome · osteoarthritis · osteoarthritis, knee · osteosarcoma · ovarian carcinoma · ovarian serous cystadenocarcinoma · pancreatic ductal adenocarcinoma · Parkinson disease · pneumonia · polyarticular juvenile idiopathic arthritis · porphyria cutanea tarda · prediabetes syndrome · pregnancy disorder with abortive outcome · primary progressive multiple sclerosis · prolactin-producing pituitary gland adenoma · prostate carcinoma · psoriasis · pulmonary tuberculosis · rectal cancer · refractory malignant neoplasm · renal cell adenocarcinoma · retinitis pigmentosa · rheumatic fever · rheumatic heart disease · rosacea · sarcoma · secondary progressive multiple sclerosis · small cell lung carcinoma · soft tissue neoplasm · sudden sensorineural hearing loss · temporal arteritis · type 1 diabetes mellitus · ulcerative colitis · undifferentiated connective tissue syndrome · urothelial carcinoma · X-linked Alport syndrome · Zellweger spectrum disorders · Borrelia infectious disease · chondrocalcinosis · chronic pancreatitis · chronic urticaria · discoid lupus erythematosus · dry eye syndrome · idiopathic recurrent pericarditis · intrinsic cardiomyopathy · lupus erythematosus · Lyme disease · ovarian hyperstimulation syndrome · palindromic rheumatism · primary antiphospholipid syndrome · respiratory tract infectious disorder · spondyloarthropathy · thrombocytopenia · viral respiratory tract infection
Investigated by
National Cancer Institute (NCI) · Abramson Cancer Center at Penn Medicine · Rutgers, The State University of New Jersey · Assistance Publique - Hôpitaux de Paris · Rutgers Cancer Institute of New Jersey · University of Utah
+433 more · Massachusetts General Hospital · NYU Langone Health · University of Pittsburgh · Assiut University · M.D. Anderson Cancer Center · National Taiwan University Hospital · Pfizer · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · The University of Texas Health Science Center at San Antonio · Abderrahmane Mami Hospital · Brigham and Women's Hospital · Dr. Stanley Ho Medical Foundation, Macau · Eshmoun Clinical Research Center · Genentech, Inc. · Health and Humanity Research Centre, Hongkong · Intermountain Health Care, Inc. · King Hussein Cancer Center · Macau University of Science and Technology Hospital · Medical Research Council · National Institutes of Health (NIH) · National University Hospital, Singapore · Peking Union Medical College Hospital · Shanghai Jinshan Hospital · Shanghai Zhongshan Hospital · Tanta University · University Hospital Tuebingen · University Hospital of Saint-Etienne · University of Manitoba · University of Medicine and Dentistry of New Jersey · University of Minnesota · Yunfeng Cheng · Zhongshan Qingpu Hospital, Fudan University · Zhongshan Wusong Hospital, Fudan University · ACDIMA Biocenter · Apsen Farmaceutica S.A. · Azidus Brasil · Baqiyatallah Medical Sciences University · Barcelona Institute for Global Health · Bernhard Nocht Institute for Tropical Medicine · Berry Consultants · Bill and Melinda Gates Foundation · BioMed Valley Discoveries, Inc · Brazilian Research In Intensive Care Network · Bristol-Myers Squibb · Children's Hospital of Fudan University · Columbia University · DSCS CRO · Datametrix · Duke University · Hamad Medical Corporation · Helsinki University Central Hospital · Hospices Civils de Lyon · Hospital Clinic of Barcelona · Hospital Israelita Albert Einstein · Hospital Sirio-Libanes · Hospital do Coracao · Institute for Research and Development of Medicinal and Food Plants of Guinea · Laboratorios Rubió · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · McGill University Health Centre/Research Institute of the McGill University Health Centre · Medical University of South Carolina · Memorial Sloan Kettering Cancer Center · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Northwestern University · Novartis Pharmaceuticals · OHSU Knight Cancer Institute · Peng Wang, MD PhD · ProgenaBiome · Radboud University Medical Center · Robert Bosch Medical Center · Sana Pharmaceutical Industry · Sanofi · Sant Pau Research Institute · all 439 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) PLAQUENIL — 1955-04-18 fda.gov ↗

Trials 339 · started per year

today
US approved 1955
1
3
1
1
2
3
8
6
10
15
9
8
10
5
10
14
10
11
139
22
15
5
14
8
9
19541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 011 trials
Phase 0 NCT06408298 Jan 2026 → Feb 2029 expected — Lionel.D.Lewis, MD Recruiting No outcome recorded
Phase 0 NCT04532346 Sep 2024 → Oct 2026 expected chronic respiratory distress with surfactant metabolism deficiency, interstitial lung disease Children's Hospital of Fudan University Recruiting No outcome recorded
Phase 0 NCT05365893 Oct 2021 → Dec 2025 overdue pancreatic ductal adenocarcinoma Fox Chase Cancer Center Active not recruiting No outcome recorded
Phase 0 NCT04340349 Feb → May 2021 malaria, toxic maculopathy due to antimalarial drugs Instituto Nacional de Rehabilitacion Unknown No outcome recorded
Phase 0 NCT04323631 Apr 2020 COVID-19 Rambam Health Care Campus Withdrawn No outcome recorded
Phase 0 NCT04329572 Apr → May 2020 COVID-19 Azidus Brasil Suspended No outcome recorded
Phase 0 NCT04348474 Apr → Jun 2020 COVID-19 Azidus Brasil Suspended No outcome recorded
Phase 0 NCT02421575 Jul 2012 → Feb 2016 prostate carcinoma Rutgers, The State University of New Jersey Terminated No outcome recorded Stop: Enrollment
Phase 0 NCT01495403 Dec 2011 → Apr 2015 cirrhosis of liver Mayo Clinic Completed No outcome recorded
Phase 0 NCT01396200 Jun 2011 → Oct 2012 plasma cell myeloma Abramson Cancer Center at Penn Medicine Completed No outcome recorded
Phase 139 trials
Phase 1 NCT07814339 Sep 2026 → Jun 2028 expected acute myeloid leukemia Rutgers, The State University of New Jersey Not yet recruiting No outcome recorded
Phase 1 NCT06776445 Jan 2024 → Jul 2025 rosacea First Affiliated Hospital of Chongqing Medical University Completed No outcome recorded
Phase 1 NCT05237843 Mar → Nov 2022 habitual spontaneous abortion Ain Shams University Unknown No outcome recorded
Phase 1 NCT04873895 Jan 2022 → Apr 2024 colorectal cancer Abramson Cancer Center at Penn Medicine Terminated No outcome recorded Stop: Enrollment
Phase 1 NCT05083780 Nov 2021 → Dec 2025 overdue malignant pancreatic neoplasm Changhoon Yoo Active not recruiting No outcome recorded
Phase 1 NCT04316169 Oct 2021 → Jan 2027 female breast carcinoma Medical College of Wisconsin Withdrawn No outcome recorded Stop: Business
Phase 1 NCT04973566 Aug 2021 → May 2022 — Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT04787991 Aug 2021 → Nov 2024 pancreatic adenocarcinoma Cancer Insight, LLC Completed No outcome recorded
Phase 1 NCT04590274 Nov 2020 → Dec 2021 COVID-19, severe acute respiratory syndrome International Brain Research Foundation Withdrawn No outcome recorded
Phase 1 NCT04497519 Sep → Oct 2020 COVID-19 University Medical Center Groningen Completed No outcome recorded
Phase 1/239 trials · 1 met primary · 2 missed
Phase 1/2 NCT05842174 Apr 2026 → Sep 2029 expected hepatocellular carcinoma VA Office of Research and Development Recruiting No outcome recorded
Phase 1/2 NCT06939582 Dec 2024 → Jun 2025 overdue mucositis Xingchen Peng Recruiting No outcome recorded
Phase 1/2 NCT06328387 Jan 2024 → Feb 2026 breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Unknown No outcome recorded
Phase 1/2 NCT05953350 Nov 2023 → May 2024 overdue — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 1/2 NCT04731051 Oct → Nov 2022 COVID-19 King Hussein Cancer Center Withdrawn No outcome recorded
Phase 1/2 NCT05119140 Jun 2022 → May 2025 overdue ulcerative colitis Icahn School of Medicine at Mount Sinai Active not recruiting No outcome recorded
Phase 1/2 NCT05036226 Mar 2022 → May 2027 expected prostate cancer Medical University of South Carolina Recruiting No outcome recorded
Phase 1/2 NCT04593758 Sep 2021 → Mar 2023 clear cell sarcoma Cornerstone Pharmaceuticals Completed No outcome recorded
Phase 1/2 NCT04911816 Jul 2021 → Jun 2027 expected pancreatic adenocarcinoma West Virginia University Recruiting No outcome recorded
Phase 1/2 NCT03929211 May 2021 → Sep 2022 myelodysplastic syndrome Wake Forest University Health Sciences Withdrawn No outcome recorded
Phase 296 trials · 2 met primary · 9 missed
Phase 2 NCT07443436 Nov 2026 → Nov 2027 expected interstitial lung disease Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 2 NCT07467252 Sep 2026 → Dec 2027 expected pulmonary tuberculosis Ministry of Health, Saudi Arabia Not yet recruiting No outcome recorded
Phase 2 NCT07825454 Sep 2026 → Dec 2029 expected breast cancer Indiana University Not yet recruiting No outcome recorded
Phase 2 NCT06971744 Dec 2025 → Jun 2028 expected ovarian serous cystadenocarcinoma Medical University of South Carolina Recruiting No outcome recorded
Phase 2 NCT07138898 Dec 2025 → Jan 2028 expected rheumatic disorder NYU Langone Health Recruiting No outcome recorded
Phase 2 NCT06350630 Jun 2025 → Dec 2027 expected IgA glomerulonephritis University Hospital of Saint-Etienne Recruiting No outcome recorded
Phase 2 NCT06949982 Mar 2025 → Apr 2027 expected colorectal cancer Sergey Orlov, MD Recruiting No outcome recorded
Phase 2 NCT06816810 Mar 2025 → Sep 2026 overdue Parkinson disease Ottawa Hospital Research Institute Not yet recruiting No outcome recorded
Phase 2 NCT06467526 Jul 2024 → May 2026 overdue sudden sensorineural hearing loss Chang Gung Memorial Hospital Not yet recruiting No outcome recorded
Phase 2 NCT05689359 Jun 2024 → Feb 2025 breast cancer, chemotherapy-induced neuropathy, female reproductive organ cancer University of Arizona Withdrawn No outcome recorded
Phase 2/321 trials · 3 met primary · 1 missed
Phase 2/3 NCT04385264 Jan → Aug 2022 COVID-19 Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland Withdrawn No outcome recorded
Phase 2/3 NCT05961202 Nov 2021 → Sep 2024 overdue myocarditis Tongji Hospital Recruiting Met primary
Phase 2/3 NCT05084872 Oct 2021 → Jan 2024 mastocytosis University Hospital, Toulouse Unknown No outcome recorded
Phase 2/3 NCT04964583 Jan → Aug 2021 COVID-19 Coordinación de Investigación en Salud, Mexico Unknown No outcome recorded
Phase 2/3 NCT04597775 Oct 2020 → Jan 2021 Orthocoronavirinae infectious disease Regional Center for Disease Control and Prevention, Jordan Unknown No outcome recorded
Phase 2/3 NCT04389359 Sep 2020 → Aug 2021 COVID-19 Cambridge University Hospitals NHS Foundation Trust Withdrawn No outcome recorded
Phase 2/3 NCT04400019 Sep → Dec 2020 COVID-19 University of Malaga Unknown No outcome recorded
Phase 2/3 NCT04437693 Aug 2020 → Aug 2021 COVID-19 Hamad Medical Corporation Unknown No outcome recorded
Phase 2/3 NCT04361318 May → Oct 2020 COVID-19 Tanta University Unknown No outcome recorded
Phase 2/3 NCT04351516 Apr → Dec 2020 COVID-19 University Hospital Tuebingen Withdrawn No outcome recorded Stop: Enrollment
Phase 370 trials · 14 missed
Phase 3 NCT07830108 Dec 2026 → Dec 2034 expected rheumatic fever, rheumatic heart disease Starship Child Health, Te Toka Tumai Auckland Not yet recruiting No outcome recorded
Phase 3 NCT07265297 Aug 2025 → Dec 2030 expected NAFLD1 National Taiwan University Hospital Recruiting No outcome recorded
Phase 3 NCT07061717 Jul 2025 → Jul 2029 expected hormone receptor-positive breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting No outcome recorded
Phase 3 NCT05799378 Jun 2024 → Dec 2028 expected systemic lupus erythematosus NYU Langone Health Recruiting No outcome recorded
Phase 3 NCT05287321 May 2022 → Dec 2026 expected preeclampsia Yoo-min Kim Recruiting No outcome recorded
Phase 3 NCT05247554 Mar 2022 → Mar 2023 pulmonary sarcoidosis Assistance Publique - Hôpitaux de Paris Unknown No outcome recorded
Phase 3 NCT04364815 Dec 2020 → May 2021 COVID-19 University of the Philippines Withdrawn No outcome recorded
Phase 3 NCT04788355 Jul → Nov 2020 pregnancy disorder Universidade do Vale do Sapucai Completed No outcome recorded
Phase 3 NCT04405921 Jul → Dec 2020 COVID-19 Centre Hôpital Universitaire Farhat Hached Unknown No outcome recorded
Phase 3 NCT04414241 Jun → Nov 2020 Orthocoronavirinae infectious disease Universidad Peruana Cayetano Heredia Completed Missed primary
Phase 434 trials · 1 met primary · 2 missed
Phase 4 NCT07352566 Aug 2026 → Jun 2030 expected atopic eczema, psoriasis University of California, San Francisco Not yet recruiting No outcome recorded
Phase 4 NCT07230028 Mar → Nov 2026 expected infectious disorder of the nervous system Radboud University Medical Center Not yet recruiting No outcome recorded
Phase 4 NCT06676384 Feb 2025 → Aug 2029 expected IgA glomerulonephritis, chronic kidney disease, immunoglobulin A vasculitis Christian Medical College, Vellore, India Recruiting No outcome recorded
Phase 4 NCT05841758 Jul 2024 → Jul 2029 expected pulmonary sarcoidosis Hospices Civils de Lyon Recruiting No outcome recorded
Phase 4 NCT05126147 Mar 2022 → Sep 2025 overdue disease of orbital part of eye adnexa National Taiwan University Hospital Recruiting No outcome recorded
Phase 4 NCT05626348 Dec 2021 → Jun 2025 overdue rheumatoid arthritis Qilu Hospital of Shandong University Recruiting No outcome recorded
Phase 4 NCT04316494 Dec 2020 → May 2025 eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis Guy's and St Thomas' NHS Foundation Trust Terminated No outcome recorded Stop: Enrollment
Phase 4 NCT04746365 Dec 2020 → Jan 2021 COVID-19 Elaraby Hospital Completed No outcome recorded
Phase 4 NCT04624269 Dec 2020 → Nov 2021 antiphospholipid syndrome, pregnancy loss, recurrent, 4 Shanghai First Maternity and Infant Hospital Unknown No outcome recorded
Phase 4 NCT04715295 Oct 2020 → May 2021 COVID-19 Yaounde Central Hospital Unknown No outcome recorded
Phase not applicable29 trials · 3 missed
— NCT06652113 Nov 2024 → Mar 2035 expected autoimmune thyroid disease, pregnancy loss, recurrent, 4 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
— NCT06389201 Aug 2024 → Aug 2029 expected nasopharyngeal carcinoma Affiliated Hospital of Nantong University Recruiting No outcome recorded
— NCT06479291 Jul 2024 → Jan 2026 overdue autoimmune thrombocytopenia Yunfeng Cheng Recruiting No outcome recorded
— NCT06479317 Apr 2024 → Jan 2026 overdue autoimmune thrombocytopenia Yunfeng Cheng Recruiting No outcome recorded
— NCT06479304 Apr 2024 → Jan 2026 overdue autoimmune thrombocytopenia Yunfeng Cheng Recruiting No outcome recorded
— NCT06319560 Mar 2024 → Jun 2026 overdue gestational diabetes, type 2 diabetes mellitus National University of Malaysia Recruiting No outcome recorded
— NCT04755322 Mar 2021 → Jul 2023 preeclampsia Assiut University Completed No outcome recorded
— NCT04466280 Aug → Sep 2020 COVID-19 Baqiyatallah Medical Sciences University Withdrawn No outcome recorded Stop: Business
— NCT04392973 May 2020 → Jan 2021 COVID-19 King Abdullah International Medical Research Center Completed Missed primary
— NCT04370015 May → Jun 2020 Orthocoronavirinae infectious disease Services Institute of Medical Sciences, Pakistan Unknown No outcome recorded
Comparator or background therapy147 trials
Phase 1 NCT04809623 Background Sep 2021 → Oct 2022 cutaneous lupus erythematosus Gilead Sciences Terminated No outcome recorded Stop: Business
Phase 1 NCT04461353 Comparator Jun → Aug 2020 COVID-19 Pulmoquine Therapeutics, Inc Completed No outcome recorded
Phase 1 NCT04976465 Background Jan 2018 → Jul 2025 overdue pregnancy disorder, systemic lupus erythematosus Qilu Hospital of Shandong University Recruiting No outcome recorded
Phase 1/2 NCT04390152 Comparator Jan 2020 → Mar 2022 acute respiratory distress syndrome BioXcellerator Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT02756546 Comparator Sep 2014 → Sep 2015 systemic lupus erythematosus Cairo University Completed No outcome recorded
Show all 147 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2020-04-24 EMS Regulatory ANVISA APROVA TERCEIRO ESTUDO CLÍNICO DA EMS PARA AVALIAR EFICÁCIA DE MEDICAMENTO NO COMBATE AO NOVO CORONAVÍRUS ems.com.br ↗
A EMS, maior laboratório farmacêutico no Brasil, 100% brasileiro, teve seu terceiro protocolo de pesquisa clínica sobre o uso da hidroxicloroquina no combate ao novo coronavírus aprovado pela Agência Nacional de Vigilância Sanitária (Anvisa).
2020-03-27 EMS Regulatory ANVISA APROVA INÍCIO DOS ESTUDOS CLÍNICOS APOIADOS PELA EMS PARA USO DE HIDROXICLOROQUINA EM PACIENTES COM CORONAVÍRUS ems.com.br ↗
São Paulo, 27 de março de 2020 – EMS, maior laboratório farmacêutico no Brasil, teve hoje dois protocolos de pesquisa clínica para uso de hidroxicloroquina em pacientes com Covid-19 aprovados pela Anvisa.
2018-07-09 Lupin Limited Regulatory Lupin receives FDA approval for generic Hydroxychloroquine Sulfate Tablets USP, 200 mg lupin.com ↗
Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Hydroxychloroquine Sulfate Tablets USP, 200 mg from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals, Inc.’s Plaquenil Tablets, 200 mg.

All press releases naming this drug 13 releases

DateIssuerRelease

Evidence & citations 34 cited values

Every value below carries the sentence it was read from. 527 sources stand behind the page.

FieldValueCited text
Known as hydroxychloroquine “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗
478

“The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and...” NCT04353037 ↗

“Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR...” NCT03411798 ↗

“The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and...” NCT04441424 ↗

“The purpose of this proposed research is to investigate the efficacy and safety of hydroxychloroquine sulfate (HCQ, Quensyl) for pediatric ILD(chILD) caused by pulmonary...” NCT03822780 ↗

“csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX...” NCT02873936 ↗

“Eligible patients in group 2 will receive oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to...” NCT04349241 ↗

“Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.” NCT04502342 ↗

“Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)” NCT04809623 ↗

“Phase I-II Clinical Trial of the Safety and Preliminary Efficacy of Hydroxychloroquine Combined With Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma” NCT02013778 ↗

“hydroxychloroquine 200 mg TID PO+ methotrexate 2.5 mg BID twice a week PO+ capecitabine 1000 mg/m2 PO BID for 14 days+ bevacizumab 7.5 mg/m2 IV on day 1, every 3 weeks.” NCT06949982 ↗

Show 468 more sources
Known as CASnr 118-42-3 (hydroxychloroquine); 737-36-4 (hydroxychloroquine sulfate) “CASnr 118-42-3 (hydroxychloroquine); 737-36-4 (hydroxychloroquine sulfate)” NCT01207739 ↗
Known as Dolquine “Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine (2 tablets of 200 mg per Dolquine® tablet) daily the first...” PMID 32727613 ↗ Jul 2020
Known as Ercoquin ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗
Known as HCQ “The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo...” NCT04329923 ↗
121

“To characterize the effects of hydroxychloroquine (HCQ) on the modulation of markers of autophagy, as measured by p62, Beclin1, LC3, and GRp170 expression, in pre- and...” NCT00962845 ↗

“The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and...” NCT04353037 ↗

“We subsequently tested the effects of transient versus chronic inhibition of autophagy with chloroquine or hydroxychloroquine (HCQ) and mTOR signaling with rapamycin (RAPA) or...” PMID 40897974 ↗ Sep 2025

“The investigators plan to evaluate a strategy of chemoprophylaxis with hydroxyloquine (HCQ) against COVID-19 infection in patients diagnosed with an immunomediated inflammatory...” NCT04330495 ↗

“This is a multi-center, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of Hydroxychloroquine Sulfate (HCQ) in adult Patients with mild to...” NCT04384380 ↗

“Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-malarial drugs that have been used since the 1960's as steroidsparing agents on the basis of a landmark study by...” NCT05841758 ↗

“This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and...” NCT06971744 ↗

“The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine...” NCT04351919 ↗

“This is an exploratory, open label, multi-center study to evaluate the efficacy of hydroxychloroquine (HCQ) (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (AZT)...” NCT04329572 ↗

“Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR...” NCT03411798 ↗

Show 111 more sources
Known as Hidroxicloroquina ClinicalTrials.gov intervention name — accepted as the source's own label NCT04330495 ↗
Known as Hydrochloroquine “Hydrochloroquine (HCQ) is a hydroxychloroquine sulfate composed of 4- amino quinoline compounds.” NCT03592823 ↗
1

“Drug: Hydrochloroquine” NCT07265297 ↗
Known as Hydroxychloroquin ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230028 ↗
Known as HYDROXYCHLOROQUINE Plaquenil “HYDROXYCHLOROQUINE Plaquenil” NCT04341727 ↗
Known as hydroxychloroquine sulfate “This is a multi-center, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of Hydroxychloroquine Sulfate (HCQ) in adult Patients with mild to...” NCT04384380 ↗
29

“The investigational product hydroxychloroquine sulfate is a 4- aminoquinoline derivative and widely used for the treatment of many rheumatic diseases” NCT04411433 ↗

“HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization” NCT05113810 ↗

“Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.” NCT04005768 ↗

“Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.” NCT03400865 ↗

“Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.” NCT04371523 ↗

“Hydroxychloroquine sulfate tablets will be given at a total daily dose of 0.2g to 0.4g based on individual weight:” NCT06652113 ↗

“Hydrochloroquine (HCQ) is a hydroxychloroquine sulfate composed of 4- amino quinoline compounds.” NCT03592823 ↗

“Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg)” NCT04005781 ↗

“Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days” NCT04374539 ↗

“Drug: Hydroxychloroquine sulfate Dose: 400 mg orally once daily Duration: 12 weeks” NCT07825454 ↗

Show 19 more sources
Known as Hydroxychloroquine Sulfate Tablets “Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis” NCT06939582 ↗
Known as Hydroxychloroquine Sulphate “Hydroxychloroquine Sulphate will be administered at a dose of 400mg twice a day on day 1 followed by 400 mg once a week for a total of 12 weeks” NCT04359537 ↗
1

“Drug: Hydroxychloroquine sulphate” NCT04005781 ↗
Known as hydroxychloroquine(HCQ) “hydroxychloroquine(HCQ)” NCT03411798 ↗
Known as Hydroxychloroquine; Plaquenil, RVG 00853 “Hydroxychloroquine; Plaquenil, RVG 00853” NCT01207739 ↗
Known as hydroxycloroquina ClinicalTrials.gov intervention name — accepted as the source's own label NCT03669367 ↗
Known as NSC-4375 ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗
Known as Oxiklorin ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗
Known as Plaquanil “Hydroxychloroquine \[Plaquanil®\] is licensed to treat rheumatoid arthritis and other inflammatory conditions; it is related to the antimalarial chloroquine.” NCT01232660 ↗
Known as Plaquenil “Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis” NCT05119140 ↗
10

“Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days.” NCT04354441 ↗

“The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab” NCT06229340 ↗

“Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)” NCT00946790 ↗

“Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days” NCT04371406 ↗

“Plaquenil (hydroxychloroquine) is an anti-malarial agent” NCT02126683 ↗

“Hydroxychloroquine sulfate, also known as Plaquenil” NCT04374552 ↗

“Hydroxychloroquine Sulfate 200 MG [Plaquenil]” NCT04392128 ↗

“hydroxychloroquine (Plaquenil) tablets” NCT00102557 ↗

“hydroxychloroquine (HCQ/ Plaquenil)” NCT04316169 ↗

“hydroxychloroquine (plaquenil®)” NCT06753565 ↗
Known as Plaquenil sulfate ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗
Known as PLAQUENILR “Hydroxychloroquine (PLAQUENILR) is an orally available autophagy inhibitor that has been used for many years to treat autoimmune diseases like lupus, sarcoidosis and rheumatoid...” NCT03979651 ↗
Known as PlaquenilTM “standard care with the addition of 400 mg hydroxychloroquine sulphate (PlaquenilTM) twice daily for seven days” PMID 32503662 ↗ Jun 2020
Known as Polirreumin ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗
Known as Quensyl “The purpose of this proposed research is to investigate the efficacy and safety of hydroxychloroquine sulfate (HCQ, Quensyl) for pediatric ILD(chILD) caused by pulmonary...” NCT03822780 ↗
2

“Name of IMP: Hydroxychloroquine sulfate (HCQ); Quensyl.” NCT04342221 ↗

“Hydroxychloroquine (e.g. Quensyl®)” NCT02779114 ↗
Known as Quinoric ChEMBL registry synonym — accepted as the source's own label CHEMBL1535 ↗